Verisign Very Resigned: Cautious Approach to New Products

Research evidence excerpt

Verisign Very Resigned: Cautious Approach to New Products

J P M O R G A N North America Equity Research

11 June 2026

Verisign Neutral

VRSN, VRSN US

Very Resigned: Cautious Approach to New Products Price (10 Jun 26):$288.09

Vertical SaaS & HealthTech

Investors often ask if VRSN will pursue a new product strategy beyond registry Alexei Gogolev AC

operations to fuel growth. We believe VRSN’s capital allocation strategy remains (1-212) 622-9391

firmly centered on shareholder returns, with limited appetite for transformative alexei.gogolev@jpmorgan.com

R&D/S&M investment cycles or M&A. Since 2018, the company’s R&D Ella Smith

expenditure has consistently hovered at 5–6% of total revenue, which does not (1-212) 622-2451

suggest a heavy internal emphasis on new product development. We view ella.smith@jpmchase.com

management as having a conservative approach to innovation, prefering to Destiny Jackson

leverage existing infrastructure and technical expertise for internal development. (1-212) 622-4360

destiny.jackson@jpmorgan.com

Such approach reflects a broader philosophy of operational focus and risk

Isabella A Camaj

discipline, meaning that new products are likely to be immaterial to both our (1-212) 834-2379

estimates and VRSN investment case over the coming years. bella.camaj@jpmorgan.com

J.P. Morgan Securities LLC

• S&M investments restrained; management does not intend to build an

enterprise sales force. CEO Jim Bidzos has repeatedly signaled that Verisign

will continue to lean on its established channel partnerships and infrastructure,

with no intent to build an enterprise sales force. Overall strategy remains

anchored in the core registry franchise, with no evidence of a shift to a

materially different sales motion.

• Prior experience with with non-core operations.